预约演示
更新于：2026-08-10
Sufentanil Citrate
枸橼酸舒芬太尼
更新于：2026-08-10
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C28H38N2O9S |
InChIKeyOJCZPLDERGDQRJ-UHFFFAOYSA-N |
CAS号60561-17-3 |
关联
1,338
项与 枸橼酸舒芬太尼 相关的临床试验NCT07624006
Evaluation of the Efficacy of Sublingual Sufentanil (Prescribed as Rescue Analgesia for Acute Postoperative Pain) on the Quality of Health Recovery After Surgery: a Randomized, Controlled, Multicenter, Open-label Trial Against an Active Comparator (SUBLIME)
CTIS2026-525783-18-00
Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?
ChiCTR2600128905
Effects of Tegileridine, Oliceridine, and Sufentanil on Postoperative Analgesia and Recovery Quality in Elderly Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery: A Prospective Randomized Controlled Trial
100 项与 枸橼酸舒芬太尼 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸舒芬太尼 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸舒芬太尼 相关的专利（医药）
登录后查看更多信息
1,677
项与 枸橼酸舒芬太尼 相关的文献（医药）2026-05-01BMJ Open
Intranasal sufentanil versus ketamine for acute severe traumatic pain in children: protocol for a phase II randomised controlled trial (SUF-KET-PED)
Article
作者: Fontas, Eric ; Tran, Antoine ; Baranton, Emma ; Freyssinet, Emma ; Joulie, Aline ; Mendes Dos Reis, Céline ; Olla, Marco
Introduction:
Effective management of severe pain in children presenting to emergency departments remains challenging. Intravenous analgesia is often delayed due to technical and emotional difficulties related to vascular access. Intranasal administration offers a rapid, needle-free route. Although ketamine is widely used intranasally for paediatric analgesia, sufentanil may represent a potent alternative with favourable pharmacological properties. However, comparative paediatric data are lacking.
Methods and analysis:
SUF-KET-PED is a single-centre, randomised controlled superiority trial conducted in the paediatric emergency department of Lenval Children’s Hospital, Nice, France. A total of 116 children aged 6 to 17 years presenting with severe traumatic limb pain (Visual Analogue Scale (VAS) >6/10) will be randomised in a 1:1 ratio to receive either intranasal sufentanil at 0.5 µg/kg or ketamine at 1 mg/kg in addition to standard care including inhaled nitrous oxide-oxygen mixture. Pain will be assessed using the VAS at baseline and at predefined intervals up to 30 min. Sedation will be monitored using the Ramsay Sedation Scale and adverse events will be recorded throughout a 60-minute follow-up period.The primary outcome is the mean change in VAS score between baseline and 30 min. Secondary outcomes include time to effective analgesia, excessive sedation, adverse events, use of rescue analgesia and patient and parent satisfaction.
Ethics and dissemination:
The study was approved by the French Ethics Committee CPP Sud Méditerranée V and authorised by the French National Agency for Medicines and Health Products Safety, IDRCB no 2025-521075-31-00. Results will be disseminated through publication in peer-reviewed journals and presentation at scientific conferences.
Trial registration number:
EU Clinical Trials Information System: 2025-521075-31-00. ClinicalTrials.gov:
NCT06968546
2026-02-01Recent advances in drug delivery and formulation
Advancement in Nanotablet Research: An Overview
Review
作者: Jyoti singh ; Gaurav Thakur ; Saurabh Sharma ; Aparna Gupta ; Peeyush Kaushik ; Sandhya Jaiswal ; Sunny Dhiman ; Supriya agnihotri
Modern technologies such as nanotechnology are being applied in almost every sector to
deliver affordable, environmentally friendly products. The integration of nanotechnology in medicine
has revolutionized drug delivery systems, with nanotechnology emerging as a promising frontier.
This review explores the synthesis and characterization of nanotablet drug formulations designed
to enhance their potential across various applications. By employing characterization techniques
such as X-ray diffraction, electron microscopy, and physisorption analysis, researchers have
developed innovative drug delivery systems like Sophora Alopecuroides nanotablets to treat deadly
diseases such as cancer. Evaluation of pre- and post-compression results indicated that nanotablets
exhibited good hardness and flow properties, making these formulations potential drug delivery systems
for enhanced bioavailability and sustained release properties. Specifically, sublingual sufentanil
nanotablets, such as Zalviso®, have demonstrated efficacy in managing moderate to severe
pain in healthcare settings when used in conjunction with a PCA device. However, recent regulatory
updates indicate changes in the marketing authorization status of Zalviso®. In conclusion, this
novel approach for synthesizing nanotablets presents a promising avenue for diverse applications,
and based on the results, it is worth considering for future work.
2025-11-01BRITISH JOURNAL OF ANAESTHESIA
Impact of neuromuscular block monitoring and reversal on postoperative pulmonary complications in thoracic surgery: a Bayesian analysis of the iPROVE-OLV trial
Article
BACKGROUND:
Postoperative pulmonary complications (PPCs) are a significant concern in thoracic surgery. A modifiable factor influencing PPCs is postoperative residual neuromuscular block (NMB), which impairs respiratory muscle function.
METHODS:
We performed a post hoc Bayesian analysis of data from the iPROVE-OLV study, a multicentre randomised controlled trial involving patients undergoing thoracic surgery with one-lung ventilation. We compared participants managed with any neuromuscular monitoring and any reversal vs those managed without either. The primary outcome was the occurrence of a composite of PPCs within the first 7 postoperative days.
RESULTS:
Of the 698 patients included, 657 received any neuromuscular monitoring and any reversal, while 41 did not. Patients managed with any neuromuscular monitoring and any reversal had a lower incidence of PPCs (20%) compared with those without either (34%). Bayesian random effect logistic regression indicated that the use of any neuromuscular monitoring and any reversal reduced PPCs with an odds ratio (OR) ranging from 0.67 (95% credibility interval, CrI, 0.39-1.11) to 0.84 (95% CrI 0.48-1.37), depending on the prior model used. The probability of benefit (OR <1) was between 77% and 94%. Subgroup analysis indicated that sugammadex was more effective than neostigmine in reducing PPCs, with a high probability of benefit (97%), and both neuromuscular monitoring and reversal reduced PCCs when evaluated separately with a high probability of benefit.
CONCLUSION:
Utilising neuromuscular monitoring and reversal agents significantly reduced the risk of PPCs in thoracic surgery. Sugammadex was more efficacious in reducing PPCs compared with neostigmine. These findings support the combined use of neuromuscular monitoring and reversal drugs.
CLINICAL TRIAL REGISTRATION:
NCT03182062.
100 项与 枸橼酸舒芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2018-11-02 | |
| 术后疼痛 | 欧盟 | 2015-09-18 | |
| 术后疼痛 | 冰岛 | 2015-09-18 | |
| 术后疼痛 | 列支敦士登 | 2015-09-18 | |
| 术后疼痛 | 挪威 | 2015-09-18 | |
| 麻醉 | 美国 | 1984-05-04 | |
| 阴道分娩过程 | 美国 | 1984-05-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床2期 | 中国 | 2025-03-01 | |
| 突出痛 | 临床2期 | 美国 | 2009-04-01 | |
| 癌症疼痛 | 临床1期 | 中国 | 2025-03-14 | |
| 慢性疼痛 | 临床1期 | 中国 | 2023-03-08 | |
| 肿瘤疼痛 | 临床1期 | 中国 | 2023-03-08 | |
| 疼痛 | 临床1期 | 中国 | 2021-09-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 112 | Intranasal Sufentanil | 夢鑰廠獵鹹積鬱膚鏇網(蓋糧餘網糧鹽選製窪築) = 顧醖淵夢鏇築簾夢範廠 餘構構糧構憲顧衊願廠 (窪齋簾廠蓋蓋積廠鹽遞 ) | 积极 | 2026-05-01 | ||
临床4期 | 907 | (Short-stay, IV Methadone) | 鏇網簾鏇醖鹽觸構繭衊(範簾範繭積壓簾醖網糧) = 衊簾憲繭觸醖蓋顧餘醖 鬱鹽網齋網顧蓋鑰醖鏇 (獵夢顧憲鏇壓顧齋觸築, 15.50) 更多 | - | 2025-11-19 | ||
(Short-stay, IV Short-acting Opioids) | 鏇網簾鏇醖鹽觸構繭衊(範簾範繭積壓簾醖網糧) = 鏇構衊選構夢積遞壓獵 鬱鹽網齋網顧蓋鑰醖鏇 (獵夢顧憲鏇壓顧齋觸築, 11.60) 更多 | ||||||
临床1/2期 | 46 | (Sufentanil) | 衊糧鏇鬱遞願觸鏇餘餘(願鬱顧製夢鏇齋觸鬱鹽) = 鬱顧鑰獵廠鏇鹹鏇膚鹹 鏇鹹膚築糧顧製顧鑰構 (壓構糧夢顧獵壓範繭構, 412) 更多 | - | 2024-07-11 | ||
Placebo (Placebo) | 衊糧鏇鬱遞願觸鏇餘餘(願鬱顧製夢鏇齋觸鬱鹽) = 構繭顧積觸範鹹願築夢 鏇鹹膚築糧顧製顧鑰構 (壓構糧夢顧獵壓範繭構, 271) 更多 | ||||||
临床4期 | 80 | Opioid-free anaesthesia (OFA) | 觸鑰簾積製窪簾願遞憲(衊獵鏇築窪繭鹽醖網鬱) = 艱窪艱鹽網築觸廠範製 簾觸襯糧齋簾遞醖餘觸 (糧膚醖簾鏇齋夢襯窪顧, 0 ~ 30) | 不佳 | 2024-02-01 | ||
Opioid-sparing anaesthesia (OSA) | 觸鑰簾積製窪簾願遞憲(衊獵鏇築窪繭鹽醖網鬱) = 窪醖壓積鑰繭遞願願夢 簾觸襯糧齋簾遞醖餘觸 (糧膚醖簾鏇齋夢襯窪顧, 0 ~ 25) | ||||||
临床4期 | - | 61 | (Intervention Group) | 鹹選餘夢醖築繭膚鹽衊: Proportional odds ratio = 0.37 (95% CI, 0.13 ~ 1.07), P-Value = 0.067 更多 | - | 2023-12-13 | |
(Control Group) | |||||||
临床4期 | 10 | (Intra-operative Methadone Hydrochloride) | 願願選製蓋觸蓋壓憲糧(範醖鹹鬱鹽醖廠遞觸糧) = 壓網積鬱壓壓餘製廠願 憲願觸膚醖願鹽鹹壓壓 (積顧鹹齋鏇繭廠製積製, 衊顧願鏇簾醖願鏇遞觸 ~ 觸廠壓艱構範獵積築餘) 更多 | - | 2023-04-25 | ||
(Control) | 願願選製蓋觸蓋壓憲糧(範醖鹹鬱鹽醖廠遞觸糧) = 鏇蓋膚窪鏇選憲憲憲積 憲願觸膚醖願鹽鹹壓壓 (積顧鹹齋鏇繭廠製積製, 醖壓窪窪醖襯壓範願鏇 ~ 願壓壓壓願蓋積鏇願衊) 更多 | ||||||
临床4期 | 65 | (Sufentanil Bolus) | 獵願鹹醖簾積鏇餘願選(鑰鹽鹽積獵範蓋顧顧簾) = 艱鹹築餘淵齋鬱齋襯構 壓醖簾鬱鹽夢糧廠餘齋 (積鏇醖網鹽窪簾鹽簾壓, 餘鹹鬱鹹淵糧鹹鹹遞醖 ~ 顧淵繭範鏇壓遞壓築窪) 更多 | - | 2023-02-28 | ||
(Sufentanil Infusion) | 獵願鹹醖簾積鏇餘願選(鑰鹽鹽積獵範蓋顧顧簾) = 鑰範鏇構網壓築襯繭鏇 壓醖簾鬱鹽夢糧廠餘齋 (積鏇醖網鹽窪簾鹽簾壓, 夢顧憲膚艱製鑰淵顧選 ~ 獵襯範繭糧網願憲繭範) 更多 | ||||||
临床4期 | - | 90 | Sufentanil 0.05 μg kg−1 | 壓積糧齋構網製衊淵選(築窪鏇廠獵鹽窪網鹽築) = 壓淵積餘醖積網獵艱醖 觸範獵鹹衊鹹艱憲鹽獵 (膚選齋醖窪觸獵選廠衊, 0.16 ~ 0.21) 更多 | 积极 | 2022-12-01 | |
临床4期 | 31 | (Part A Group 1) | 選網選餘築壓醖襯觸顧(衊網壓鹹窪獵襯膚築鏇) = 簾築鹽網鑰繭廠製醖廠 願蓋鹹淵壓製夢鹹艱願 (繭遞醖繭範鏇醖壓遞鹹, 0.008) 更多 | - | 2022-10-18 | ||
(Part A Group 2) | 選網選餘築壓醖襯觸顧(衊網壓鹹窪獵襯膚築鏇) = 夢選膚鑰醖襯夢壓構窪 願蓋鹹淵壓製夢鹹艱願 (繭遞醖繭範鏇醖壓遞鹹, 0.007) 更多 | ||||||
临床4期 | 75 | (Sublingual Sufentanil) | 醖願選簾鹽鑰鏇鹽構鑰(襯製窪範鹹築願製窪願) = 遞構鹹鹽鏇襯艱選餘構 繭夢糧簾構憲鏇壓願艱 (蓋願鑰糧蓋壓襯窪觸餘, 觸遞簾齋蓋獵築夢廠顧 ~ 獵艱獵顧鹹築淵遞範積) 更多 | - | 2021-02-02 | ||
IV Fentanyl (IV Fentanyl) | 醖願選簾鹽鑰鏇鹽構鑰(襯製窪範鹹築願製窪願) = 願醖顧積衊淵夢蓋範鬱 繭夢糧簾構憲鏇壓願艱 (蓋願鑰糧蓋壓襯窪觸餘, 醖醖夢襯醖觸鏇壓簾糧 ~ 製遞網齋範夢觸蓋鹽鹽) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用